Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis in Children|Airway Clearance Impairment - 8 Years to 18 Years (Child, Adult)
Interventions
Device: Simeox|Other: CCPT
Outcome measures
Change in total lung resistance|Change in central lung resistance|Change in peripheral lung resistance|Change in total lung reactance|Change in area of reactance (AX)|Change in total score of Cystic Fibrosis Questionnaire-Revised (CFQ-R)|Change in respiratory domain score of Cystic Fibrosis Questionnaire Revised (CFQ-R) questionnaire|Change in Forced Expiratory Volume in 1 second (FEV1)|Change in Forced Vital Capacity (FVC)|Change in Residual Volume (RV)|Change in Maximal Expiratory Flow (MEF) at 25, 50 and 75% of expired volume|Change in Mean Mid Expiratory Flow (MMEF)|Change in lung clearance index (LCI)|Pulmonary exacerbation|Adverse events